Peanut Allergy

DBV Technologies recently provided updates on its Viaskin Peanut Program for children and toddlers, announcing recruitment for the VITESSE study and progress in the COMFORT Toddlers supplemental safety study.

The FDA has approved Palforzia, an oral immunotherapy designed to protect children aged 1 to 3 years with peanut allergies from reactions caused by accidental exposure, according to a press release.

The FDA has approved Palforzia for children aged 1 to 3 years who have a peanut allergy that has been diagnosed by a physician, according to a press release from its manufacturer, Stallergenes Greer.

The House Appropriations Committee adopted an amendment that would require the inclusion of peanut-containing products into the Special Supplemental Nutrition Program for Women, Infants, and Children.

Food Allergy Research and Education is asking the public to boycott Mars products over what the organization says is a harmful media campaign.

A recent study found that health care professionals were increasingly able to identify infants and young children with anaphylaxis by following modified criteria.

Significant disparities exist between patients with peanut allergies who are currently receiving oral immunotherapy and those who are not, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Families of children with peanut allergies that pursued oral immunotherapy cited remission and the potential for disease modification as their reason, according to a study published in The Journal of Allergy and Immunology: In Practice.

New guidance was established for clinicians in the U.K. in order to implement the use of Palforzia in oral immunotherapy for patients with a peanut allergy, according to a study published in Clinical & Experimental Allergy.

Gut microbiomes in children with food allergy may differ from those without food allergy, with fewer differences seen in younger children, according to a study published in Annals of Allergy, Asthma and Immunology.